跳至主要内容
临床试验/NCT00614679
NCT00614679已完成1 期

A Novel Catheter Lock Solution for Treatment of Tunneled Hemodialysis Catheter-Associated Bacteremia

University of California, San Diego3 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2006年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
18
试验地点
3
主要终点
Treatment success within 90 days

研究概览

简要总结

The primary objective is to investigate the ability of systemic intravenous antibiotic plus antibiotic/anti-biofilm (i.e. N-acetylcysteine) lock catheter technique in eradicating uncomplicated catheter associated bacteremia and salvaging the infected vascular catheter. Secondary objectives include duration to clearance of bacteremia, future recurrence of bacteremia, need for catheter removal and death.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 100 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients who have an indwelling hemodialysis catheter for 10 or more days and evidence of a catheter associated bloodstream infection as evidenced by 1)quantitative blood cultures obtained through the lumen of the catheter yield concentrations of bacterial colonies that are 5 or more fold higher than peripheral blood cultures, or 2)blood cultures obtained through the lumen of the catheter becomes positive 2 or more hours earlier than peripheral blood cultures.

排除标准

  • Patients will be excluded if 1) they are unable or unwilling to provide informed consent, 2) have evidence of a complicated bacteremia such as endocarditis, septic thrombophlebitis, septic emboli, osetoemylitis, deep seated abscesses etc 3)evidence of an exit site infection around the catheter such as a pus pocket, drainage or erythema. 4) patient is allergic to NAC or the proposed antibiotic (if patient is allergic to minocycline, tigecycline will not be used). 5) patient is pregnant or will become pregnant.

研究组 & 干预措施

1

Experimental

single arm trial of experimental catheter lock solution

干预措施: catheter lock solution consisting of N-acetylcystein, tigecycline and heparin (Drug)

结局指标

主要结局

Treatment success within 90 days

时间窗: 90 days

次要结局

  • catheter salvage(90 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Saima Aslam

Associate Professor

University of California, San Diego

研究点 (3)

Loading locations...

相似试验

A Novel Catheter Lock Solution for Treatment of... | 临床试验